{"hands_on_practices": [{"introduction": "A cornerstone of safe prescribing in older adults is accurately accounting for age-related changes in drug metabolism and elimination. Because muscle mass declines with age, a 'normal' serum creatinine can mask significantly reduced renal function. This practice exercise focuses on a fundamental clinical skill: using the Cockcroft-Gault equation to estimate creatinine clearance and applying this information to make crucial dose adjustments for renally-cleared medications to prevent toxicity [@problem_id:4716566].", "problem": "An 84-year-old woman weighing $55 \\ \\mathrm{kg}$ with a serum creatinine $SCr = 0.9 \\ \\mathrm{mg/dL}$ is being initiated on lithium carbonate and gabapentin for bipolar depression with comorbid neuropathic pain. In older adults, renal function commonly declines with age, and many psychotropics that are predominantly renally cleared require dose adjustments to avoid toxicity. Use the Cockcroft–Gault method with the standard female adjustment to estimate renal function, taking into account that in non-obese older adults the actual body weight is used. Then, using the principles that for primarily renally eliminated drugs maintenance dose at steady state is approximately proportional to renal clearance, and that geriatric practice targets lower lithium trough concentrations, provide a reasoned proposal for conservative initial dose adjustments for lithium and gabapentin that would be expected to achieve similar exposure as in normal renal function while minimizing toxicity risk. Assume oral bioavailability is not meaningfully altered in this patient and that the serum creatinine should not be arbitrarily rounded. Round your creatinine clearance to four significant figures and express it in $\\mathrm{mL/min}$. For the purpose of grading, report only the numerical value of the estimated creatinine clearance as your final answer, without units.", "solution": "The problem is deemed valid. It is scientifically grounded, well-posed, and objective. It presents a clear clinical scenario with all necessary quantitative data to perform the requested calculation. The task involves estimating renal function using a standard, formalizable clinical equation (Cockcroft-Gault) and discussing dose adjustments based on established pharmacokinetic principles. The problem does not violate any fundamental scientific principles, is not ambiguous, and contains no contradictory or incomplete information.\n\nThe central task is to estimate the patient's creatinine clearance ($CrCl$) using the Cockcroft-Gault equation. The formula is given by:\n$$CrCl = \\frac{(140 - \\mathrm{Age}) \\times \\mathrm{Weight}}{72 \\times SCr}$$\nwhere Age is in years, Weight is in $\\mathrm{kg}$, and serum creatinine ($SCr$) is in $\\mathrm{mg/dL}$. The resulting $CrCl$ is in units of $\\mathrm{mL/min}$.\n\nThe problem provides the following data for the patient:\n- Age $= 84$\n- Weight $= 55 \\ \\mathrm{kg}$\n- $SCr = 0.9 \\ \\mathrm{mg/dL}$\n- Sex $=$ Female\n\nThe problem specifies that for female patients, the calculated value must be multiplied by a correction factor of $0.85$. It also states to use the patient's actual body weight, which is the standard of practice for non-obese individuals.\n\nFirst, we substitute the patient's data into the base formula.\n$$CrCl_{\\text{base}} = \\frac{(140 - 84) \\times 55}{72 \\times 0.9}$$\n$$CrCl_{\\text{base}} = \\frac{56 \\times 55}{64.8}$$\n$$CrCl_{\\text{base}} = \\frac{3080}{64.8} \\approx 47.53086 \\ \\mathrm{mL/min}$$\n\nNext, we apply the correction factor for a female patient:\n$$CrCl_{\\text{female}} = CrCl_{\\text{base}} \\times 0.85$$\n$$CrCl_{\\text{female}} = 47.53086 \\ \\mathrm{mL/min} \\times 0.85$$\n$$CrCl_{\\text{female}} \\approx 40.40123 \\ \\mathrm{mL/min}$$\n\nThe problem requires the result to be rounded to four significant figures. Therefore, the estimated creatinine clearance is $40.40 \\ \\mathrm{mL/min}$.\n\nThis value of $CrCl \\approx 40.40 \\ \\mathrm{mL/min}$ indicates moderate renal impairment. For context, Stage $3$ Chronic Kidney Disease is defined by a Glomerular Filtration Rate (GFR) of $30-59 \\ \\mathrm{mL/min/1.73m^2}$. In clinical practice, the $CrCl$ is commonly used as a direct surrogate for GFR for the purpose of drug dosing. This estimated renal function is clinically significant, especially given the patient's \"normal\" serum creatinine level of $0.9 \\ \\mathrm{mg/dL}$, and it highlights the necessity of accounting for age-related decline in muscle mass (and thus creatinine production) and renal function.\n\nRegarding the reasoned proposal for dose adjustments, the principle is that the maintenance dose ($D_{m}$) of a drug primarily eliminated by the kidneys is directly proportional to the patient's renal clearance. This relationship can be approximated as:\n$$D_{m, \\text{adjusted}} = D_{m, \\text{normal}} \\times \\frac{CrCl_{\\text{patient}}}{CrCl_{\\text{normal}}}$$\nAssuming a \"normal\" $CrCl$ for a healthy young adult is approximately $100-120 \\ \\mathrm{mL/min}$, the dose for this patient should be reduced to roughly $35\\%$ to $40\\%$ of the standard dose.\n\nFor lithium, a drug with a narrow therapeutic index and over $95\\%$ renal clearance, this reduction is critical. Furthermore, geriatric practice guidelines recommend targeting lower serum trough concentrations (e.g., $0.4-0.6 \\ \\mathrm{mEq/L}$ vs. the standard $0.6-1.2 \\ \\mathrm{mEq/L}$). Therefore, a highly conservative approach is warranted. A typical starting dose of $300 \\ \\mathrm{mg}$ twice daily would be excessive. A starting dose of $150 \\ \\mathrm{mg}$ once daily, with very slow titration and frequent therapeutic drug monitoring, would be a more appropriate initial strategy.\n\nFor gabapentin, which is also eliminated almost entirely by the kidneys, dose adjustment is required. Published dosing guidelines for gabapentin provide specific recommendations based on $CrCl$ ranges. For a $CrCl$ in the range of $30-59 \\ \\mathrm{mL/min}$, the recommended total daily dose is significantly lower than for patients with normal renal function. A conservative starting dose, such as $100 \\ \\mathrm{mg}$ once or twice daily, would be prudent to minimize dose-related central nervous system side effects like somnolence and dizziness, followed by cautious titration based on efficacy and tolerability.\n\nThe final answer required for grading is the numerical value of the estimated creatinine clearance.", "answer": "$$\\boxed{40.40}$$", "id": "4716566"}, {"introduction": "Polypharmacy is the norm, not the exception, in geriatric care, and understanding the cumulative impact of a medication regimen is critical. This exercise introduces the concept of anticholinergic burden, a common source of iatrogenic cognitive impairment in older adults. By calculating a cumulative risk score and using a simple linear model, you will practice quantifying this abstract risk and translating it into a concrete, predicted clinical outcome, reinforcing the principles behind deprescribing [@problem_id:4716662].", "problem": "A 78-year-old person with mild neurocognitive disorder presents for medication review. You are asked to quantify the cumulative anticholinergic exposure of the current regimen and relate that exposure to cognitive trajectory using foundational definitions of additive burden and least-squares modeling. Assume that Anticholinergic Cognitive Burden (ACB) points are assigned per agent, independent of dose, and cumulative burden is the sum of per-agent points. Use the following ACB point assignments for the listed drugs: paroxetine $\\rightarrow 3$, oxybutynin $\\rightarrow 3$, lisinopril $\\rightarrow 0$, metformin $\\rightarrow 0$, simvastatin $\\rightarrow 0$. The patient’s regimen is: paroxetine $20$ mg daily, oxybutynin $5$ mg twice daily, lisinopril $10$ mg daily, metformin $500$ mg twice daily, simvastatin $20$ mg nightly.\n\nTo model the empirical association between anticholinergic exposure and cognitive change, consider a reference cohort of similarly aged adults with paired values of cumulative ACB scores $x$ and observed $6$-month Mini-Mental State Examination (MMSE) change $y$ (defined as $\\text{MMSE}_{6\\text{-mo}} - \\text{MMSE}_{\\text{baseline}}$; negative values indicate decline). The cohort pairs $(x,y)$ are:\n$(0,-0.1)$, $(1,-0.4)$, $(2,-0.8)$, $(3,-1.2)$, $(4,-1.6)$, $(6,-2.3)$, $(7,-2.6)$.\n\nStarting from the core definitions that cumulative ACB is an additive sum and that a simple linear relationship $y$ as a function of $x$ can be estimated by minimizing the sum of squared residuals over the cohort, carry out the following:\n- Compute the patient’s cumulative ACB score $x_{\\text{patient}}$ from the provided regimen using the given agent point assignments.\n- Using the cohort data and the least-squares criterion, determine the best-fitting simple linear model $y = a + b x$, then use it to predict the patient’s $6$-month MMSE change $\\hat{y}_{\\text{patient}}$ given $x_{\\text{patient}}$.\n\nRound your final predicted change to $3$ significant figures. Express your final answer in Mini-Mental State Examination (MMSE) points.", "solution": "The problem requires a two-part calculation. First, the patient's cumulative Anticholinergic Cognitive Burden (ACB) score must be computed. Second, a simple linear regression model must be derived from provided cohort data to predict the patient's cognitive change based on this score.\n\nPart 1: Calculation of the Patient's Cumulative ACB Score\n\nThe patient's medication regimen is given as: paroxetine $20$ mg daily, oxybutynin $5$ mg twice daily, lisinopril $10$ mg daily, metformin $500$ mg twice daily, and simvastatin $20$ mg nightly.\n\nThe problem states that the cumulative ACB score is the sum of per-agent points, independent of dosage. The given ACB point assignments are:\n- paroxetine: $3$ points\n- oxybutynin: $3$ points\n- lisinopril: $0$ points\n- metformin: $0$ points\n- simvastatin: $0$ points\n\nOnly medications with non-zero ACB scores contribute to the cumulative burden. For this patient, these are paroxetine and oxybutynin.\nThe patient's cumulative ACB score, denoted as $x_{\\text{patient}}$, is the sum of the scores for these two agents:\n$$x_{\\text{patient}} = (\\text{ACB score for paroxetine}) + (\\text{ACB score for oxybutynin})$$\n$$x_{\\text{patient}} = 3 + 3 = 6$$\n\nPart 2: Linear Regression and Prediction\n\nThe problem asks to model the relationship between the cumulative ACB score ($x$) and the $6$-month change in Mini-Mental State Examination (MMSE) score ($y$) using a simple linear model of the form $y = a + b x$. The coefficients $a$ (intercept) and $b$ (slope) are to be determined by the method of least squares, which minimizes the sum of squared residuals, $S = \\sum_{i=1}^{n} (y_i - (a + b x_i))^2$.\n\nThe provided cohort data consists of $n=7$ pairs of $(x_i, y_i)$:\n$(0, -0.1)$, $(1, -0.4)$, $(2, -0.8)$, $(3, -1.2)$, $(4, -1.6)$, $(6, -2.3)$, $(7, -2.6)$.\n\nTo find the coefficients $a$ and $b$, we must first calculate the following sums from the data: $\\sum x_i$, $\\sum y_i$, $\\sum x_i^2$, and $\\sum x_i y_i$.\n\n- $\\sum x_i = 0 + 1 + 2 + 3 + 4 + 6 + 7 = 23$\n- $\\sum y_i = (-0.1) + (-0.4) + (-0.8) + (-1.2) + (-1.6) + (-2.3) + (-2.6) = -9.0$\n- $\\sum x_i^2 = 0^2 + 1^2 + 2^2 + 3^2 + 4^2 + 6^2 + 7^2 = 0 + 1 + 4 + 9 + 16 + 36 + 49 = 115$\n- $\\sum x_i y_i = (0)(-0.1) + (1)(-0.4) + (2)(-0.8) + (3)(-1.2) + (4)(-1.6) + (6)(-2.3) + (7)(-2.6)$\n  $\\sum x_i y_i = 0 - 0.4 - 1.6 - 3.6 - 6.4 - 13.8 - 18.2 = -44.0$\n\nThe least-squares estimates for $b$ and $a$ are given by the formulas:\n$$b = \\frac{n(\\sum x_i y_i) - (\\sum x_i)(\\sum y_i)}{n(\\sum x_i^2) - (\\sum x_i)^2}$$\n$$a = \\bar{y} - b\\bar{x} = \\frac{\\sum y_i}{n} - b \\frac{\\sum x_i}{n}$$\n\nSubstituting the calculated sums with $n=7$:\n$$b = \\frac{7(-44.0) - (23)(-9.0)}{7(115) - (23)^2} = \\frac{-308 + 207}{805 - 529} = \\frac{-101}{276}$$\nNow, we calculate $a$:\n$$a = \\frac{-9.0}{7} - \\left(\\frac{-101}{276}\\right)\\left(\\frac{23}{7}\\right) = \\frac{1}{7}\\left[-9.0 + \\frac{(101)(23)}{276}\\right] = \\frac{1}{7}\\left[\\frac{-9.0 \\times 276 + 2323}{276}\\right]$$\n$$a = \\frac{1}{7}\\left[\\frac{-2484 + 2323}{276}\\right] = \\frac{1}{7}\\left[\\frac{-161}{276}\\right] = \\frac{-23}{276}$$\n\nThus, the best-fitting simple linear model is:\n$$y(x) = -\\frac{23}{276} - \\frac{101}{276}x$$\n\nFinally, we use this model to predict the $6$-month MMSE change for the patient, $\\hat{y}_{\\text{patient}}$, given their ACB score of $x_{\\text{patient}} = 6$.\n$$\\hat{y}_{\\text{patient}} = y(6) = -\\frac{23}{276} - \\frac{101}{276}(6)$$\n$$\\hat{y}_{\\text{patient}} = \\frac{-23 - (101 \\times 6)}{276} = \\frac{-23 - 606}{276} = \\frac{-629}{276}$$\n\nTo obtain the final numerical answer, we perform the division:\n$$\\hat{y}_{\\text{patient}} \\approx -2.2789855...$$\n\nThe problem requires rounding the final predicted change to $3$ significant figures.\n$$\\hat{y}_{\\text{patient}} \\approx -2.28$$\nThis predicted value represents a decline of approximately $2.28$ points on the MMSE scale over a $6$-month period.", "answer": "$$\\boxed{-2.28}$$", "id": "4716662"}, {"introduction": "Effective geriatric psychopharmacology requires dynamic management, as a patient's clinical status and medication regimen are rarely static. This advanced problem simulates a common and high-stakes clinical scenario: adjusting a narrow-therapeutic-index drug in the face of both declining organ function and a new drug-drug interaction. You will integrate multiple pharmacokinetic principles—clearance, volume of distribution, and half-life—to not only calculate a conservative dose reduction but also to devise a rational monitoring schedule based on the drug's new kinetic profile [@problem_id:4716619].", "problem": "An inpatient, $78$ years old and weighing $70$ kg, has been stable on a chronic lithium regimen that produced a therapeutic trough when his renal function was previously unimpaired. He is now readmitted with a measured creatinine clearance (CrCl) of $35$ mL/min and is started on a thiazide diuretic that is known to decrease lithium renal clearance. Assume the following foundational pharmacokinetic facts and conversions as the base for your reasoning:\n- Under linear kinetics at steady state, the average steady-state concentration $C_{\\mathrm{ss,avg}}$ is proportional to the ratio of the maintenance dose $D$ to total body clearance $Cl$, that is, $C_{\\mathrm{ss,avg}} \\propto D/Cl$.\n- Lithium is almost exclusively renally cleared, so its total body clearance is approximately proportional to creatinine clearance. Use $Cl \\approx \\mathrm{CrCl}$ after unit conversion.\n- A thiazide diuretic decreases lithium clearance by $30\\%$ on average in older adults; model this as a multiplicative factor of $(1-0.30)$ applied to renal clearance.\n- For lithium in older adults, the apparent volume of distribution $V_d$ is approximately $0.7$ L/kg.\n- The terminal half-life is $t_{1/2} = (\\ln 2)\\, V_d / Cl$ under one-compartment linear kinetics.\n- Unit conversion: $1$ mL/min equals $0.06$ L/h.\n\nFurther, to operationalize a conservative approach appropriate for geriatric patients with interacting diuretics, you will:\n- Target the lower end of the therapeutic window by applying a safety factor $s = 0.80$ to the dose that would otherwise maintain the prior $C_{\\mathrm{ss,avg}}$.\n- Define the initial therapeutic drug monitoring frequency as at least one serum lithium level per lithium half-life.\n\nBefore the current change, assume the patient’s reference creatinine clearance was $100$ mL/min with no interacting diuretic. Using only the principles and facts above, compute:\n1) The fractional lithium dose reduction, defined as $r = 1 - \\frac{D_{\\mathrm{new}}}{D_{\\mathrm{old}}}$, where $D_{\\mathrm{new}}$ is the conservative maintenance dose under the new conditions and $D_{\\mathrm{old}}$ is the prior maintenance dose.\n2) The monitoring frequency in checks per week, defined as $f = \\frac{7}{t_{1/2,\\mathrm{new}}/\\mathrm{day}}$.\n\nRound both $r$ and $f$ to two significant figures. Express your final answer as a row vector with two entries, the first being $r$ (unitless) and the second being $f$ (checks per week). Do not include units in the final boxed answer.", "solution": "The problem is valid as it is scientifically grounded in established pharmacokinetic principles, is well-posed with sufficient information for a unique solution, and is expressed in objective, formal language. We proceed with the solution in two parts.\n\nPart 1: Calculation of the fractional lithium dose reduction, $r$.\n\nThe average steady-state concentration, $C_{\\mathrm{ss,avg}}$, is given to be proportional to the ratio of the maintenance dose, $D$, to the total body clearance, $Cl$. We can write this as $C_{\\mathrm{ss,avg}} = k \\frac{D}{Cl}$, where $k$ is a proportionality constant.\n\nLet the prior (old) state be denoted by the subscript 'old' and the new state by 'new'. We have:\n$$C_{\\mathrm{ss,avg,old}} = k \\frac{D_{\\mathrm{old}}}{Cl_{\\mathrm{old}}}$$\nThe patient was stable, so this represents a therapeutic concentration. The goal is to determine a new dose, $D_{\\mathrm{new}}$, that is conservative for the new conditions. The problem states that this is achieved by applying a safety factor, $s = 0.80$, to the dose that would otherwise maintain the prior $C_{\\mathrm{ss,avg}}$. Let this hypothetical dose be $D'_{\\mathrm{new}}$.\n\nTo maintain the prior concentration under the new clearance conditions, we would require:\n$$C_{\\mathrm{ss,avg,old}} = k \\frac{D'_{\\mathrm{new}}}{Cl_{\\mathrm{new}}}$$\nEquating the two expressions for $C_{\\mathrm{ss,avg,old}}$ gives:\n$$k \\frac{D_{\\mathrm{old}}}{Cl_{\\mathrm{old}}} = k \\frac{D'_{\\mathrm{new}}}{Cl_{\\mathrm{new}}}$$\n$$\\implies D'_{\\mathrm{new}} = D_{\\mathrm{old}} \\frac{Cl_{\\mathrm{new}}}{Cl_{\\mathrm{old}}}$$\nThe new conservative dose, $D_{\\mathrm{new}}$, is obtained by applying the safety factor $s$:\n$$D_{\\mathrm{new}} = s \\cdot D'_{\\mathrm{new}} = s \\cdot D_{\\mathrm{old}} \\frac{Cl_{\\mathrm{new}}}{Cl_{\\mathrm{old}}}$$\nThe ratio of the new dose to the old dose is therefore:\n$$\\frac{D_{\\mathrm{new}}}{D_{\\mathrm{old}}} = s \\frac{Cl_{\\mathrm{new}}}{Cl_{\\mathrm{old}}}$$\nThe fractional dose reduction, $r$, is defined as $r = 1 - \\frac{D_{\\mathrm{new}}}{D_{\\mathrm{old}}}$. We first need to calculate the ratio of clearances, $\\frac{Cl_{\\mathrm{new}}}{Cl_{\\mathrm{old}}}$.\n\nLithium clearance, $Cl$, is stated to be approximately proportional to creatinine clearance, $\\mathrm{CrCl}$.\nFor the old state: $\\mathrm{CrCl}_{\\mathrm{old}} = 100$ mL/min, with no interacting diuretic. Thus, $Cl_{\\mathrm{old}} \\propto \\mathrm{CrCl}_{\\mathrm{old}} = 100$ mL/min.\nFor the new state: $\\mathrm{CrCl}_{\\mathrm{new}} = 35$ mL/min, and a thiazide diuretic is introduced which decreases lithium clearance by $30\\%$. This corresponds to a multiplicative factor of $(1 - 0.30) = 0.70$.\nTherefore, the new clearance is proportional to the new creatinine clearance and the diuretic effect:\n$$Cl_{\\mathrm{new}} \\propto \\mathrm{CrCl}_{\\mathrm{new}} \\times (1 - 0.30) = 35 \\, (\\text{mL/min}) \\times 0.70$$\nThe ratio of the clearances is:\n$$\\frac{Cl_{\\mathrm{new}}}{Cl_{\\mathrm{old}}} = \\frac{\\mathrm{CrCl}_{\\mathrm{new}} \\times 0.70}{\\mathrm{CrCl}_{\\mathrm{old}}} = \\frac{35 \\times 0.70}{100} = \\frac{24.5}{100} = 0.245$$\nNow we can find the dose ratio:\n$$\\frac{D_{\\mathrm{new}}}{D_{\\mathrm{old}}} = s \\frac{Cl_{\\mathrm{new}}}{Cl_{\\mathrm{old}}} = 0.80 \\times 0.245 = 0.196$$\nFinally, we calculate the fractional dose reduction $r$:\n$$r = 1 - \\frac{D_{\\mathrm{new}}}{D_{\\mathrm{old}}} = 1 - 0.196 = 0.804$$\nRounding to two significant figures, we get $r \\approx 0.80$.\n\nPart 2: Calculation of the monitoring frequency, $f$.\n\nThe monitoring frequency is defined as $f = \\frac{7}{t_{1/2,\\mathrm{new}}/\\mathrm{day}}$, where $t_{1/2,\\mathrm{new}}$ is the new terminal half-life in days. We must first calculate $t_{1/2,\\mathrm{new}}$ using the formula $t_{1/2} = (\\ln 2) V_d / Cl$. This requires the absolute values of the new volume of distribution, $V_d$, and the new clearance, $Cl_{\\mathrm{new}}$.\n\nThe patient's weight is $70$ kg, and the apparent volume of distribution, $V_d$, for lithium in older adults is given as $0.7$ L/kg.\n$$V_d = 0.7 \\, \\frac{\\text{L}}{\\text{kg}} \\times 70 \\, \\text{kg} = 49 \\, \\text{L}$$\nNext, we calculate the absolute value of the new clearance, $Cl_{\\mathrm{new}}$, in units of L/h.\nThe new creatinine clearance is $\\mathrm{CrCl}_{\\mathrm{new}} = 35$ mL/min. Using the conversion factor $1$ mL/min = $0.06$ L/h:\n$$\\mathrm{CrCl}_{\\mathrm{new}} = 35 \\, \\frac{\\text{mL}}{\\text{min}} \\times 0.06 \\, \\frac{\\text{L/h}}{\\text{mL/min}} = 2.1 \\, \\frac{\\text{L}}{\\text{h}}$$\nThe problem states $Cl \\approx \\mathrm{CrCl}$ after unit conversion. This value of $2.1$ L/h represents the clearance due to renal function alone. The thiazide diuretic reduces this by $30\\%$:\n$$Cl_{\\mathrm{new}} = 2.1 \\, \\frac{\\text{L}}{\\text{h}} \\times (1 - 0.30) = 2.1 \\, \\frac{\\text{L}}{\\text{h}} \\times 0.70 = 1.47 \\, \\frac{\\text{L}}{\\text{h}}$$\nNow, we can calculate the new half-life, $t_{1/2,\\mathrm{new}}$, in hours:\n$$t_{1/2,\\mathrm{new}} = \\frac{(\\ln 2) V_d}{Cl_{\\mathrm{new}}} = \\frac{(\\ln 2) \\times 49 \\, \\text{L}}{1.47 \\, \\text{L/h}}$$\nThe fraction simplifies: $\\frac{49}{1.47} = \\frac{4900}{147} = \\frac{100 \\times 49}{3 \\times 49} = \\frac{100}{3}$.\n$$t_{1/2,\\mathrm{new}} = (\\ln 2) \\frac{100}{3} \\, \\text{hours}$$\nTo find the monitoring frequency, we need the half-life in days. There are $24$ hours in a day.\n$$t_{1/2,\\mathrm{new}} \\, (\\text{in days}) = \\frac{(\\ln 2) \\frac{100}{3}}{24} = (\\ln 2) \\frac{100}{72} = (\\ln 2) \\frac{25}{18} \\, \\text{days}$$\nThe monitoring frequency, $f$, is the number of checks per week (7 days):\n$$f = \\frac{7 \\, \\text{days/week}}{t_{1/2,\\mathrm{new}} \\, (\\text{in days})} = \\frac{7}{(\\ln 2) \\frac{25}{18}} = \\frac{7 \\times 18}{25 \\ln 2} = \\frac{126}{25 \\ln 2}$$\nNow we compute the numerical value:\n$$f \\approx \\frac{126}{25 \\times 0.693147} \\approx \\frac{126}{17.328675} \\approx 7.2712$$\nRounding to two significant figures, we get $f \\approx 7.3$.\nThe results for the two parts are $r \\approx 0.80$ and $f \\approx 7.3$.", "answer": "$$\\boxed{\\begin{pmatrix} 0.80 & 7.3 \\end{pmatrix}}$$", "id": "4716619"}]}